Trials in Progress and Late-Breaking Abstracts
Late-breaking abstract submission opens Feb. 14, 2022

In 2022, ASGCT is offering a new topic category as well as the opportunity to submit late-breaking abstracts.

Gene and Cell Therapy Trials in Progress

Abstracts describing ongoing Trials in Progress (trials that have not reached the primary endpoint) may now be submitted for consideration for the ASGCT Annual Meeting. These abstracts will provide an opportunity for members of the community to learn and understand planned and ongoing clinical trials, and to foster collaboration when appropriate.

Your Trial in Progress abstract should include:

  • A clinical trial registry number
  • Scientific rationale for the trial to be presented
  • Trial eligibility criteria
  • Any interim data that is available for presentation

Late-Breaking Abstracts

Late-breaking abstract submission will run from Monday, Feb. 14 through Friday, March 18. Late-breaking abstracts should present data that is high impact, groundbreaking, innovative, and newsworthy. The late-breaking abstract deadline is not intended to be an extension of the general submission deadline.

The late-breaking abstract deadline is final, and no abstracts will be accepted after this deadline. No changes or withdrawals will be allowed for late-breaking abstracts.

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.